The CRONIC-PPF Faculty

	Eva BÖHM (former STURM) Assoc. Prof. Dr. rer. nat. (PhD) Neutrophil heterogeneity and functional plasticity in progressive pulmonary fibrosis
Head of Research Unit "Cell signaling pathways in inflammatory lung diseases" Division of Pharmacology, Otto Loewi Research Centre, Medical University of Graz, Neue Stiftingtalstraße 6, 8010 Graz Phone: +43-316-385 74103, ✉ e-mail WWW: Forschungsportal Med Uni Graz ORCID: 0000-0003-4898-884X PubMed: PubMed (nih.gov)
• Profile      • Curriculum vitae     • Publications

List of publications:

• For a full list of publications see → Fodok Med Uni Graz

10 most significant publications:

1. Nayak BB, Bärnthaler T, Rajesh R, Teppan J, Gogg T, Douschan P, Kneidinger N, van der Does AM, Hiemstra PS, Heinemann A, Böhm EM: Brepocitinib, a selective TYK2/JAK1 inhibitor, mitigates neutrophilic inflammation and glucocorticoid receptor-β expression in COPD. Am J Physiol Lung Cell Mol Physiol, 2026; 330(2):​L178–L197.
2. Teppan J, Bärnthaler T, Farzi A, Durrington H, Gioan-Tavernier G, Platt H, Wolf P, Heinemann A, Böhm E: The molecular circadian clock of eosinophils: a potential therapeutic target for asthma. Am J Physiol Cell Physiol, 2025; 328(5):​C1394–C1408.
3. Teppan J, Schwanzer J, Rittchen S, Bärnthaler T, Lindemann J, Nayak B, Reiter B, Luschnig P, Farzi A, Heinemann A, Sturm E: The disrupted molecular circadian clock of monocytes and macrophages in allergic inflammation. Front Immunol, 2024; 15:​1408772.
4. Luschnig P, Kienzl M, Roula D, Pilic J, Atallah R, Heinemann A, Sturm EM: The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. Biochem Pharmacol, 2021; 192:​114690.
5. Roula D, Theiler A, Luschnig P, Böhm GJ, Tomazic PV, Marsche G, Heinemann A, Böhm EM: Apolipoprotein A-IV acts as an endogenous anti-inflammatory protein and is reduced in treatment-naïve allergic patients and allergen-challenged mice. Allergy, 2020; 75(2):​392–402.
6. Theiler A, Bärnthaler T, Platzer W, Richtig G, Peinhaupt M, Rittchen S, Kargl J, Ulven T, Marsh LM, Marsche G, Schuligoi R, Böhm EM, Heinemann A: Butyrate ameliorates allergic airway inflammation by limiting eosinophil trafficking and survival. J Allergy Clin Immunol, 2019; 144(3):​764–776.
7. Frei RB, Luschnig P, Parzmair GP, Peinhaupt M, Schranz S, Fauland A, Wheelock CE, Heinemann A, Böhm EM: Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice. Allergy, 2016; 71(7):​944–956.
8. Sturm EM, Parzmair GP, Radnai B, Frei RB, Sturm GJ, Hammer A, Schuligoi R, Lippe IT, Heinemann A: Phosphoinositide-dependent protein kinase 1 (PDK1) mediates potent inhibitory effects on eosinophils. Eur J Immunol, 2015; 45(5):​1548–1559.
9. Sturm EM, Dyer KD, Percopo CM, Heinemann A, Rosenberg HF: Chemotaxis of bone marrow derived eosinophils in vivo: a novel method to explore receptor-dependent trafficking in the mouse. Eur J Immunol, 2013; 43(8):​2217–2228.
10. Sturm EM, Schratl P, Schuligoi R, Konya V, Sturm GJ, Lippe IT, Peskar BA, Heinemann A: Prostaglandin E₂ inhibits eosinophil trafficking through E-prostanoid 2 receptors. J Immunol, 2008; 181(10):​7273–7283.

03.04.2026 CRONIC-PPF · Doctoral Programme “Clinical & Research Oriented Network for Innovative Classification of Progressive Pulmonary Fibrosis”